Pfizer’s pneumonia shot patent challenged in India

9af2461f8d9581e5c06c5b851183a7a3India’s High Court in Delhi has moved to February 2018 the final decision on allowing Pfizer to be the only pharmaceutical company selling pneumococcal conjugate vaccine (PCV 13) to the Indian government, a plan that was contested by an international humanitarian group providing medical aid.

The PCV 13 is intended for India’s universal immunisation programme for children. Last August, the court held that Pfizer could have patent rights in India for the vaccine, barring local manufacturers from selling cheaper versions of PCV 13, marketed as Prenevar 13. In November, Médecins Sans Frontières (MSF) or Doctors without Borders obtained the deferment by arguing in court that the patent does not meet the standards laid out by India’s laws.

Read the full article in SciDev